IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 TC≥50% NSCLC who were disease-free at 5 years (5yDF) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)

被引：0

作者：

Felip, E. ^{[1
]}

Vallieres, E. ^{[2
]}

Gologordko, O. ^{[3
]}

Martinez-Marti, A. ^{[1
]}

Zhou, C. ^{[4
]}

Altorki, N. K. ^{[5
]}

Rittmeyer, A. ^{[6
]}

Chella, A. ^{[7
]}

Reck, M. ^{[8
]}

Schuette, W. ^{[9
]}

Okada, M. ^{[10
]}

Liersch, R. ^{[11
]}

Teixeira, M. E. ^{[12
]}

Bennett, E. ^{[13
,14
]}

Gitlitz, B. J. ^{[14
,15
]}

Srivastava, M. ^{[14
,16
]}

Ballinger, M. ^{[14
,17
]}

Zhu, C. ^{[14
,17
]}

Crama, L. ^{[18
]}

Wakelee, H. ^{[19
]}

机构：

[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Oncol, Barcelona, Spain

[2] Swedish Canc Inst, Med Oncol, Seattle, WA USA

[3] MI Zaporizhzhia Reg Clin Oncol Dispensary, Oncol, Zaporizhzhia SMU Ch Oncol, Zaporizhzhia, Ukraine

[4] Tongji Univ, Affiliated Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China

[5] New York Presbyterian Hosp, Weill Cornell Med, Dept Cardiothorac Surg, New York, NY USA

[6] LKI Lungen Fachklin Immenhausen, Dept Oncol, Immenhausen, Germany

[7] Azienda Osped Univ Pisana, Pneumol Unit, Pisa, Italy

[8] German Ctr Lung Res, Thorac Oncol Dept, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany

[9] Hosp Martha Maria Halle Doelau, Med, Halle, Germany

[10] Hiroshima Univ Hosp, Hiroshima, Japan

[11] Clemenshosp Munster, Munster, Germany

[12] Hosp CUF Descobertas, Lisbon, Portugal

[13] Genentech Inc, Proc Dev Oncol, San Francisco, CA USA

[14] Roche Grp, San Francisco, CA USA

[15] Genentech Inc, PDO Dept, San Francisco, CA USA

[16] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA USA

[17] Genentech Inc, San Francisco, CA USA

[18] Roche Farma SA, Med Affairs Dept, Madrid, Spain

[19] Stanford Univ, Stanford Canc Inst, Dept Oncol, Sch Med, Stanford, CA USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1271

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1212P

引用

页码：S780 / S781

页数：2

共 8 条

[1] IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
Zhou, C.
Das Thakur, M.
Srivastava, M. K.
Zou, W.
Xu, H.
Ballinger, M.
Felip, E.
Wakelee, H.
Altorki, N. K.
Reck, M.
Liersch, R.
Kryzhanivska, A.
Harada, M.
Tanaka, H.
Hamm, J.
McCune, S.
McNally, V.
Bennett, E.
Gitlitz, B.
Novello, S.
ANNALS OF ONCOLOGY, 2021, 32 : S1374 - S1374
[2] IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC
Zhou, C.
Altorki, N.
Vallieres, E.
Felip, E.
Zuo, Y.
Howland, M.
Xia, F.
Hoang, T.
Sandler, A.
Wakelee, H.
ANNALS OF ONCOLOGY, 2016, 27
[3] Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study
Felip, E.
Altorki, N. K.
Zhou, C.
Vallieres, E.
Vynnychenko, I. O.
Akopov, A.
Martinez-Marti, A.
Chella, A.
Bondarenko, I.
Ursol, G.
Levchenko, E.
Kislov, N.
Liersch, R.
Belleli, R.
McNally, V. A.
Bennett, E.
Gitlitz, B. J.
Wakelee, H.
ANNALS OF ONCOLOGY, 2022, 33 : S71 - S71
[4] Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study
Felip, Enriqueta
Altorki, Nasser
Zhou, Caicun
Vallieres, Eric
Vynnychenko, Ihor
Akopov, Andrey
Martinez-Marti, Alex
Chella, Antonio
Bondarenko, Igor
Ursol, Grygorii
Levchenko, Evgeny
Kislov, Nikolay
Liersch, Ruediger
Belleli, Rossella
Mcnally, Virginia
Bennett, Elizabeth
Gitlitz, Barbara
Wakelee, Heather
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 146 - 147
[5] IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care
Reck, Martin
Srivastava, Minu K.
Wakelee, Heather A.
Felip, Enriqueta
Altorki, Nasser K.
Csoszi, Tibor
Moiseyenko, Vladimir
Akopov, Andrey
Smolin, Alexey
Chella, Antonio
Vallieres, Eric
Martinez-Marti, Alex
Zou, Wei
McNally, V.
Bennett, Elizabeth
Prizant, Hen
Nabet, Barzin
Ballinger, Marcus
Gitlitz, Barbara J.
Zhou, Caicun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
Wakelee, H.
Reck, M.
Felip, E.
Altorki, N. K.
Vallieres, E.
Liersch, R.
Oizumi, S.
Tanaka, H.
Hamm, J. T.
McCune, S.
Bennett, E.
Gitlitz, B. J.
McNally, V. A.
Novello, S.
Ballinger, M.
Zou, W.
Nabet, B.
Srivastava, M.
Zhou, C.
ANNALS OF ONCOLOGY, 2024, 35 : S779 - S780
[7] IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
Felip, E.
Vallieres, E.
Zhou, C.
Wakelee, H.
Bondarenko, I.
Sakai, H.
Saito, H.
Ursol, G.
Kawaguchi, K.
Liu, Y.
Levchenko, E.
Kislov, N.
Reck, M.
Liersch, R.
McNally, V. A.
Zhu, Q.
Ding, B.
Bennett, E.
Gitlitz, B.
Altorki, N. K.
ANNALS OF ONCOLOGY, 2021, 32 : S1319 - S1319
[8] IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Wakelee, Heather A.
Altorki, Nasser K.
Zhou, Caicun
Csoszi, Tibor
Vynnychenko, Ihor O.
Goloborodko, Oleksandr
Rittmeyer, Achim
Reck, Martin
Martinez-Marti, Alex
Kenmotsu, Hirotsugu
Chen, Yuh-Min
Chella, Antonio
Sugawara, Shunichi
Fu, Chenqi
Ballinger, Marcus
Deng, Yu
Srivastava, Minu K.
Bennett, Elizabeth
Gitlitz, Barbara Jenifer
Felip, Enriqueta
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8035 - LBA8035

← 1 →